Head OfficeCLINUVEL Pharmaceuticals Limited, Tel: +61 3 9660 4900 |
UK officeWesley House, Tel: +44 1372 860 765 |
US OfficePO BOX 7388, Tel: +1 372 860 765 |
Singapore office9 Temasek Blvd #29-01 |
Swiss OfficeZugerstrasse 76a, Tel: +41 41 763 1782 |
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA‐DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million. CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), a first‐in‐class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been approved by the European Commission for treating adults with EPP.
Based in Melbourne, Australia, CLINUVEL has operations in Europe, the US and Singapore.
Click here to read more
CLINUVEL maintains its ASX shareholder registry with Computershare. For all enquiries related to your shareholding, contact:
The Registrar
Computershare Investor Services Pty Limited
GPO Box 2975
Australia
(Aus) 1300 555 159 (International) +61 (0)3 9415 4062
Click here to read more
Click here to read more
CLINUVEL is listed on the Australian Securities Exchange under the ticker code CUV.
Change /
Last updated |
Open |
High |
Volume |
Market Cap |
Previous Close |
Low |
Turnover |
52 week range- |
Latest Quarterly Report (Appendix 4C) |
Q4 2017 - Calendar year |
Cash and financial assets at end of Quarter |
AUD $27.94 million |
Click here to read more